Try our beta test site
41 studies found for:    GRN163L
Show Display Options
Rank Status Study
1 Active, not recruiting Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis;   Myeloid Malignancies
Intervention: Drug: Imetelstat
2 Completed Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Conditions: Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Astrocytoma, Grade II;   Ependymoma;   Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma;   Oligodendroglioma;   Brainstem Tumors
Intervention: Drug: imetelstat sodium
3 Completed A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: GRN163L
4 Completed Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
Condition: Chronic Lymphoproliferative Diseases
Intervention: Drug: GRN163L
5 Completed Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: Imetelstat Sodium (GRN163L)
6 Withdrawn Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Conditions: Childhood Hepatoblastoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma
Interventions: Drug: imetelstat sodium;   Other: laboratory biomarker analysis
7 Completed Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Imetelstat (7.5 mg/kg);   Drug: lenalidomide standard of care;   Drug: Imetelstat (9.4 mg/kg)
8 Completed A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: GRN163L in combination with trastuzumab
9 Completed Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Imetelstat Sodium (GRN163L)
10 Completed Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
Condition: Solid Tumor Malignancies
Intervention: Drug: Imetelstat Sodium (GRN163L)
11 Completed Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Imetelstat Sodium (GRN163L)
12 Completed Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Interventions: Drug: imetelstat;   Drug: Bevacizumab
13 Completed
Has Results
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: AMG 706;   Drug: octreotide
14 Completed Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Condition: Locally Recurrent or Metastatic Breast Cancer
Interventions: Drug: Imetelstat sodium;   Drug: Bevacizumab;   Drug: Paclitaxel
15 Suspended Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Condition: Primary Myelofibrosis
Interventions: Drug: Imetelstat 9.4 milligram/kilogram (mg/kg);   Drug: Imetelstat 4.7 mg/kg
16 Terminated An Open Label Treatment Extension Study of AMG 706
Condition: Solid Tumors
Intervention: Drug: AMG 706
17 Completed Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
Condition: Advanced Gastrointestinal Stromal Tumor
Intervention: Drug: AMG 706
18 Completed Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
Conditions: Essential Thrombocythemia;   Polycythemia Vera
Intervention: Drug: Imetelstat
19 Terminated Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Motesanib;   Drug: Placebo;   Drug: Paclitaxel;   Drug: Carboplatin
20 Recruiting Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Imetelstat;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.